FIELD: pharmaceuticals; medicine.
SUBSTANCE: subject 1 is a stable liquid pharmaceutical composition with a pH of 5 to 6 containing a human anti-TSLP antibody or its antigen-binding fragment at a concentration of 1 to 300 mg/ml; a pharmaceutically acceptable buffer at a concentration of 5 to 100 mmol/l; arginine or its pharmaceutically acceptable salt at a concentration of 700 mmol/l or less and a surfactant in an amount of from 0.001 to 1 wt./vol.% Subject 2 is using the composition for the treatment of asthma.
EFFECT: technical result consists in the stability of the pharmaceutical composition containing the fully human type T7-27, which is a human anti-TSLP antibody.
20 cl, 5 dwg, 26 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| LIQUID COMPOSITION CONTAINING ANTIBODY TO HUMAN INTERLEUKIN-4 RECEPTOR ALPHA | 2020 |
|
RU2814172C2 |
| ANTIBODY CONTAINING PREPARATION | 2017 |
|
RU2748046C2 |
| METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2793783C1 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PRODUCTION | 2020 |
|
RU2795973C1 |
| STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENT METHODS | 2012 |
|
RU2563346C2 |
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PREPARATION | 2020 |
|
RU2788949C1 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
